Every Cabbage AI Express (NBD AI Express): An investor asked a question on the investor interaction platform: "Hello, Board Secretary. I saw that Chutian Technology mentioned that the vaccine appointment channels opened and immediately sold out. Is this a true reflection of the current influenza vaccine market? If so, why have the stock market performances of the company and its subsidiaries been lukewarm?"
Hualan Bio (002007.SZ) replied on the investor interaction platform on December 11th that, according to public data from the National Institutes for Food and Drug Control (NIFDC), the company has obtained lot release approval for 55 batches of influenza vaccines so far this year, ranking among the top domestically in terms of the number of approved batches. Since October, and especially November, public awareness of influenza vaccination has significantly increased. Demand orders from CDCs (Centers for Disease Control and Prevention) across the country have risen significantly compared to the same period last year. The company's influenza vaccine inventory, particularly the quadrivalent influenza virus split vaccine, has been depleted rapidly. To meet market demand, the company has been working overtime, increasing the sub-packaging of multiple batches of the quadrivalent influenza virus split vaccine and submitting them for lot release approval. These batches are expected to be released onto the market soon after completing the approval process.

https://finance.eastmoney.com/a/202512113589060511.html